Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ryplazim for congenital plasminogen deficiency
NCT02690714Phase 3Completed
- Sponsor
- Prometic Biotherapeutics Ltd
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of plasminogen in congenital plasminogen deficiency, sponsored by Prometic Biotherapeutics Ltd. Primary endpoints: Overall Clinical Success in Number and Size of Lesions at 48 weeks and Percentage of Participants Achieving Target Plasminogen Activity Trough Levels at 12 weeks. Started May 2016; status: completed.
02
Drugs
plasminogen
03
Conditions
congenital plasminogen deficiency
Beyond the preview
Go deeper on NCT02690714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690714.